Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Lotte Biologics Completes Songdo Plant 1, Accelerates Global CDMO Market Expansion

Lotte Biologics has completed construction of its first biopharmaceutical manufacturing facility at its Songdo Bio Campus in Incheon, marking a major milestone in its expansion into the global contract development and manufacturing organization (CDMO) market.The company held an opening ceremony on November 18, attended by Lotte Group Chairman Shin Dong-bin, Lotte Biologics Co-CEOs James Park and…

Lotte Biologics has successfully completed the construction of its first biopharmaceutical manufacturing facility, Plant 1, at its Songdo Bio Campus in Incheon, marking a significant step in its expansion into the global contract development and manufacturing organization (CDMO) market. The opening ceremony, held on November 18, was attended by high-profile guests including Lotte Group Chairman Shin Dong-bin, Co-CEOs James Park and Shin Yoo-yeol, government officials, and industry representatives.

The facility's completion not only establishes a robust domestic manufacturing base for Lotte Group's biotechnology business but also aligns with the company's strategic vision to become a long-term manufacturing partner offering quality, advanced technology, and reliability to global customers. Early contract wins, including a major agreement with a global pharmaceutical company and a 10-year deal with Alvotech, have bolstered Lotte Biologics' initial production outlook by securing manufacturing contracts before the plant's official opening.

Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at koreaittimes.com →

More in Finance & Markets

More from Wednesday 18 November →